DEFR14A: Processa Pharmaceuticals Discloses Executive Pay Versus Performance in Proxy Statement Supplement

Processa Pharmaceuticals provides a supplement to its definitive proxy statement, detailing the relationship between executive compensation and company performance metrics like total shareholder return and net income.

Summary

• Processa Pharmaceuticals filed a supplement to its definitive proxy statement on April 29, 2024, related to the Annual Meeting of Stockholders to be held on June 28, 2024.
• The supplement provides a Pay Versus Performance Table and related disclosures, as required by SEC rules for smaller reporting companies.
• The table includes data for 2021, 2022, and 2023, showing the Summary Compensation Table Total and Compensation Actually Paid (CAP) for the Principal Executive Officers (PEOs) and average Non-PEO NEOs.
• David Young was the PEO during 2021, 2022, and from January 1, 2023, through August 8, 2023, after which George Ng became the PEO.
• The CAP is calculated by adjusting the amounts reported in the Summary Compensation Table for stock and option award values, changes in fair value, and other factors.
• The table also includes the value of an initial $100 investment based on the Total Shareholder Return (TSR) of the company and the Net Income (Loss) in millions of dollars.
• For example, in 2023, David Young's Summary Compensation Table Total was $108,876, but his Compensation Actually Paid was $(16,297), while George Ng's Summary Compensation Table Total was $472,849, and his Compensation Actually Paid was $428,849.
• The company's net income (loss) was $(11.122) million in 2023, $(27.474) million in 2022, and $(11.427) million in 2021.
• Graphs showing the relationship of compensation actually paid to PEOs and non-PEO NEOs to TSR and net income are included in the proxy materials.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily presenting factual data related to executive compensation and company performance. The negative net income figures temper any potential positive sentiment.

Negatives

• The company experienced net losses in 2021, 2022 and 2023.
• The value of a $100 investment in the company's stock on January 1, 2021, decreased to $5 in 2023.

Risks

• The Pay Versus Performance disclosure highlights the potential misalignment between executive compensation and company financial performance, particularly given the net losses reported.
• Fluctuations in stock and option award values can significantly impact the Compensation Actually Paid to executives.

Future Outlook

The document does not contain specific forward-looking statements beyond the scheduled Annual Meeting of Stockholders.

Industry Context

The disclosure aligns with SEC regulations requiring companies to provide transparency on executive compensation and its relationship to company performance, a common practice in the pharmaceutical industry.

Comparison to Industry Standards

• Pay versus performance disclosures are now standard practice for publicly traded companies, especially since the Dodd-Frank Act mandated greater transparency.
• Comparing Processa's executive compensation and performance metrics to similar-sized pharmaceutical companies would provide a more comprehensive assessment of its compensation practices.
• Companies like Catalyst Pharmaceuticals or Adamas Pharmaceuticals, with similar market caps, could serve as benchmarks for evaluating Processa's compensation structure and performance alignment.

Management Changes

Stakeholder Impact

• Shareholders can use the Pay Versus Performance information to assess whether executive compensation is aligned with the company's performance.
• Employees may be interested in the executive compensation structure and how it compares to their own compensation.
• The company's financial performance impacts its ability to invest in research and development, which affects its long-term prospects.

Next Steps

• Stockholders will vote on various proposals at the Annual Meeting on June 28, 2024.

Key Dates

Keywords

proxy statement, executive compensation, pay versus performance, total shareholder return, net income, Processa Pharmaceuticals, David Young, George Ng, NEOs